Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $658000.0.

  • Amicus Therapeutics' Amortization of Deferred Charges rose 1463.41% to $658000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 1317.58%. This contributed to the annual value of $2.3 million for FY2024, which is 1353.21% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Amortization of Deferred Charges of $658000.0 as of Q3 2025, which was up 1463.41% from $630000.0 recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Amortization of Deferred Charges high stood at $721000.0 for Q3 2023, and its period low was $531000.0 during Q1 2024.
  • In the last 5 years, Amicus Therapeutics' Amortization of Deferred Charges had a median value of $638000.0 in 2021 and averaged $626105.3.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 14025.97% in 2021, then crashed by 2038.98% in 2024.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Amortization of Deferred Charges stood at $638000.0 in 2021, then grew by 5.17% to $671000.0 in 2022, then fell by 20.12% to $536000.0 in 2023, then increased by 11.38% to $597000.0 in 2024, then rose by 10.22% to $658000.0 in 2025.
  • Its Amortization of Deferred Charges was $658000.0 in Q3 2025, compared to $630000.0 in Q2 2025 and $606000.0 in Q1 2025.